SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001176256-19-000342
Filing Date
2019-11-19
Accepted
2019-11-19 14:55:10
Documents
7
Period of Report
2019-11-19

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN ISSUER FOR THE PERIOD ENDED NOVEMBER 19, 2019 nymox6kmpm.htm 6-K 5461
2 NOTICE OF ANNUAL GENERAL MEETING ON DECEMBER 17, 2019 exhibit99-1.htm EX-99.1 2922
3 INFORMATION CIRCULAR exhibit99-2.htm EX-99.2 97568
4 FORM OF PROXY exhibit99-3.htm EX-99.3 21549
5 cpulogo.jpg GRAPHIC 4237
6 exhibit99-3x1x1.jpg GRAPHIC 12567
7 exhibit99-3x1x2.jpg GRAPHIC 5626
  Complete submission text file 0001176256-19-000342.txt   159820
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 191230807
SIC: 2835 In Vitro & In Vivo Diagnostic Substances